Market Research Logo

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016’, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria
    • The report reviews pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Paroxysmal Nocturnal Hemoglobinuria therapeutics and enlists all their major and minor projects
    • The report assesses Paroxysmal Nocturnal Hemoglobinuria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Paroxysmal Nocturnal Hemoglobinuria pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Paroxysmal Nocturnal Hemoglobinuria Overview
    Therapeutics Development
    Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview
    Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies
    Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
    Achillion Pharmaceuticals, Inc.
    Akari Therapeutics, Plc
    Alexion Pharmaceuticals Inc
    Alnylam Pharmaceuticals, Inc.
    Amgen Inc.
    Amyndas Pharmaceuticals LLC
    Apellis Pharmaceuticals Inc
    Epirus Biopharmaceuticals, Inc.
    Novartis AG
    Omeros Corporation
    Ra Pharmaceuticals, Inc.
    Regenesance BV
    The International Biotechnology Center (IBC) Generium
    Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ACH-4471 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALN-CC5 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALXN-1210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMY-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APL-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APL-9 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Coversin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GNR-045 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NM-9405 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-721 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-906 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RA-101348 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RA-101495 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    regenemab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Target Complement C3 for Immunology, PNH and CNS Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tesidolumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects
    Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products
    Paroxysmal Nocturnal Hemoglobinuria - Product Development Milestones
    Featured News & Press Releases
    Aug 10, 2016: Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model
    Aug 04, 2016: Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System
    Jul 13, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
    Jul 12, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
    Jul 06, 2016: Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin
    Jun 23, 2016: Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor
    Jun 10, 2016: Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
    Jun 10, 2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
    Jun 10, 2016: Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association
    Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    May 19, 2016: Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
    May 19, 2016: Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress
    May 19, 2016: Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated
    May 19, 2016: Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association
    May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Akari Therapeutics, Plc, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amgen Inc., H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Novartis AG, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Omeros Corporation, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Regenesance BV, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects, H2 2016
    Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report